Showing 3391-3400 of 5646 results for "".
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2018 AAOpthttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2018-aaopt/2479707/Johnson & Johnson Vision will highlight new data at the 2018 American Academy of Optometry Annual Meeting (Academy 2018), held November 7-10 in San Antonio, Texas. Two paper presentations highlighting visual performance of photochromic contact lenses were designated among the “Most Newsworthy
- Oyster Point Announces Positive Results From Two Phase 2b Clinical Trials of Investigational Treatments for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-positive-results-from-two-phase-2b-clinical-trials-of-investigational-treatments-for-dry-eye-disease/2479733/Oyster Point Pharma announced results from the ONSET and RAINIER studies, two separate phase 2b clinical trials evaluating the company’s novel therapies for the treatment of dry eye disease (DED). Both studies, presented at the Ophthalmology Innovation Summit (OIS) meeting in Chicago, demonstrate
- First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitishttps://modernod.com/news/first-patient-screened-in-mallinckrodt-phase-4-trial-of-h-p-acthar-gel-for-severe-noninfectious-intermediate-uveitis-posterior-uveitis-or-panuveitis/2479736/Mallinckrodt confirmed screening of the first patient in the company’s phase 4, multicenter, multiple-dose, open label study to assess the effects of H.P. Acthar Gel as
- Melt Pharmaceuticals Initiates Clinical Development Program for its Patented MK Melt Conscious Sedation Drug Candidatehttps://modernod.com/news/melt-pharmaceuticals-initiates-clinical-development-program-for-its-patented-mk-melt-conscious-sedation-drug-candidate/2479764/Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three arm comparator study at the American Academy of Op
- Increasing Surgery Volume Will Fuel Single-Use Ophthalmic Surgical Device Markethttps://modernod.com/news/increasing-surgery-volume-will-fuel-single-use-ophthalmic-surgical-device-market/2479784/According to Market Scope research, two factors will drive healthy growth in the single-use ophthalmic surgical product market over the next 5 years: an aging world population, which will lead to steady growth in ophthalmic surgeries, and rising concerns over cross-contamination. Market Sc
- Konan Medical USA Acquires objectiveFIELD Objective Perimeterhttps://modernod.com/news/konan-medical-usa-acquires-objectivefield-objective-perimeter/2479795/Konan Medical USA has acquired objectiveFIELD, an FDA-cleared device designed to assess the human visual field in an objective and non-contact manner. The device was acquired from the Australian National University (ANU), includes novel features licensed from Seeing Machine
- Optovue Showcases First OCT Angiography Metrics and Non-Contact Method for Corneal Measurements at Vision Expo Westhttps://modernod.com/news/optovue-showcases-worlds-first-oct-angiography-metrics-and-non-contact-method-for-corneal-measurements-at-vision-expo-west/2479832/Optovue showcased its AngioAnalytics platform, the world’s first OCT angiography (OCTA) blood vessel measurement technology to help clinicians manage diseases that cause progressive blindness, and 3D PAR, its 3-dimensional projection artifact removal software at Vision Expo West 2018. The
- MacuLogix Launches AMD Academyhttps://modernod.com/news/maculogix-launches-amd-academy/2479861/MacuLogix has launched its AMD Academy, an online learning community for current AdaptDx users, delivering video-based product training and a user forum to facilitate discussion of best practices and answers to user questions. “MacuLogix provides extensive, in-person training to eac
- Report: Takeda May Sell Shire Assets to Reduce Debt Following $62 Billion Purchasehttps://modernod.com/news/report-takeda-may-sell-shire-assets-to-reduce-debt-following-62-billion-purchase/2479892/According to people close to the situation, Takeda is considering selling Shire’s eye care business, including the dry eye disease treatment Xiidra (lifitegrast), once it completes the purchase of the company, Bloomberg
- New Joystick for the Keratograph 5M With Release Functionhttps://modernod.com/news/new-joystick-for-the-keratograph-5m-with-release-function/2479900/The Oculus Keratograph 5M now comes equipped with a new joystick, which includes a release function. The new feature enables the user to capture images and video sequences with the push of a button on the device. No need any more to switch to the mouse – the user’s hand stays resting on the new